SEOUL Oct 4 Samsung BioLogics Co Ltd said on
Tuesday its planned initial public offering is expected to raise
up to 2.25 trillion won ($2.04 billion).
Samsung BioLogics, Samsung Group's biopharmaceutical
contract manufacturing unit, said in a regulatory filing that it
is expected to offer 16.5 million shares via the initial public
offering, with about 11 million new shares issued and about 5.5
million existing shares being floated.
The offering has an indicative range of 113,000-136,000 won
per share, the company said.
($1 = 1,102.6200 won)
(Reporting by Joyce Lee; Editing by Muralikumar Anantharaman)